- Home
- PMEC vs LITS Comparison
PMEC vs LITS Comparison
Compare PMEC & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMEC | LITS |
|---|---|---|
| Founded | 1984 | 2000 |
| Country | Singapore | United States |
| Employees | N/A | 4 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.4M | 25.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | PMEC | LITS |
|---|---|---|
| Price | $0.63 | $0.88 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 154.1K | ★ 520.2K |
| Earning Date | 07-24-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $0.69 |
| 52 Week High | $2.44 | $3.03 |
Technical Indicators
Market Signals| Indicator | PMEC | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 47.57 | 47.68 |
| Support Level | $0.59 | $0.69 |
| Resistance Level | $0.82 | $1.23 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 56.47 | 63.62 |
Price Performance
Historical ComparisonAbout PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.